(Total Views: 357)
Posted On: 07/31/2019 10:00:40 AM
Post# of 33
$DMPI News Article - DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM) https://marketwirenews.com/news-releases/delm...06410.html
(0)
(0)
My Twitter: WhyteStocks
